PRIMARY OBJECTIVE:
I. To conduct a phase 2 clinical trial to evaluate whether combination treatment with
belinostat and decitabine and cedazuridine (ASTX727) shows preliminary evidence of clinical
activity in unresectable or metastatic conventional chondrosarcoma (CS) using an objective
response rate endpoint.
SECONDARY OBJECTIVES:
I. To evaluate the toxicity profile associated with the belinostat and ASTX727. II. To
evaluate the progression free survival (PFS) associated with the belinostat and ASTX727.
III. To evaluate the toxicity profile, objective response rate and progression free survival
among the initial six patients treated with belinostat and SGI-110 (guadecitabine) prior to
Amendment 5 in which ASTX727 was substituted for SGI-110 (guadecitabine).
CORRELATIVE OBJECTIVES:
I. To determine the IDH1/2 mutational status of subject's tumors and to evaluate for a
relationship between presence of IDH1/2 mutation and clinical benefit from study treatment.
II. To conduct ribonucleic acid sequencing (RNAseq) analysis using baseline and on-treatment
tissue biopsies to study the effects of study treatment on CS gene expression patterns and
identify candidate genes which may underlie treatment efficacy.
III. To evaluate for changes in global deoxyribonucleic acid (DNA) methylation levels using
baseline and on-treatment biopsies and correlate changes in global methylation with clinical
benefit from study treatment.
IV. To use multiplex immunohistochemistry to interrogate the immune microenvironment in
baseline and on-treatment tissue biopsies to define changes in infiltrating immune cell
subsets and PD-L1/major histocompatibility complex (MHC) expression by immune and tumor cells
associated with study treatment.
OUTLINE:
Patients receive guadecitabine subcutaneously (SC) or ASTX727 orally (PO) on days 1-5.
Patients also receive belinostat intravenously (IV) over 30 minutes on days 1-5. Cycles
repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients
also undergo a tumor biopsy at baseline (within 21 days of the first cycle) and during cycle
2 (on day 3, 4, or 5). In addition, patients undergo magnetic resonance imaging (MRI) or
computed tomography (CT) scans every 2 cycles (8 weeks) while receiving guadecitabine or
ASTX727 and belinostat.
After completion of study treatment, patients are followed up every 3 months for 24 months.
Inclusion Criteria:
- Patients must have biopsy-proven conventional chondrosarcoma (CS) which is:
- Either metastatic or locally advanced and unresectable, and
- Measurable at study entry according to Response Evaluation Criteria in Solid
Tumors (RECIST) version 1.1 criteria, and
- Amenable to biopsy with imaging guidance at no or acceptable risk to the patient
as defined by institutional guidelines for research-related biopsies or the
treating investigator's assessment
- In addition, the following criteria must be met:
- Patients must have at least one lesion measurable by RECIST version 1.1
criteria which has not been previously irradiated
- Patients who have histologic evidence of grade 1 chondrosarcoma only must
either be symptomatic from their disease in the opinion of the treating
investigator or demonstrate radiographic evidence of disease progression in
the 3 months prior to initiation of study treatment
- Note: Pathology review and confirmation of diagnosis will occur at the site
enrolling the patient on this study
- Patients may have been treated with any number of prior systemic therapies. Because
there are no Food and Drug Administration (FDA)-approved treatments for this disease,
patients who have received no prior systemic therapy are also eligible. However,
disease must be deemed surgically unresectable
- Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)
- Absolute neutrophil count >= 1,000/mm^3
- Hemoglobin 8 g/dL
- Platelet count >= 75,000/mm^3
- Total bilirubin =< 1.5 x institutional upper limit of normal (ULN)
- Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase
[SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])
=< 2 x institutional ULN
- Creatinine =< 1.5 x institutional ULN OR glomerular filtration rate (GFR) >= 45
mL/min/1.73 m^2
- Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral
therapy with undetectable viral load within 6 months are eligible for this trial
- For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral
load must be undetectable on suppressive therapy, if indicated
- Patients with a history of hepatitis C virus (HCV) infection must have been treated
and cured. For patients with HCV infection who are currently on treatment, they are
eligible if they have an undetectable HCV viral load
- Patients with treated brain metastases are eligible if follow-up brain imaging after
central nervous system (CNS)-directed therapy shows no evidence of progression, if
patients have been clinically asymptomatic, and if patients have not received systemic
corticosteroids for at least 28 days. Patients with brain metastases not meeting these
criteria are not eligible
- Patients must be disease-free of prior invasive malignancies for > 5 years, with the
exception of curatively-treated basal cell or squamous cell carcinoma of the skin or
carcinoma in situ of the cervix.
- NOTE: If there is a history of prior malignancy, patients must not be receiving
other specific treatment for that cancer
- Patients with known history or current symptoms of cardiac disease, or history of
treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac
function using the New York Heart Association Functional Classification. To be
eligible for this trial, patients should be class 2B or better
- The effects of belinostat and SGI-110 (guadecitabine) or ASTX727 on the developing
human fetus are unknown. For this reason, and because the DNA methyltransferase
inhibitor decitabine, the active metabolite of SGI-110 (guadecitabine) and a component
of ASTX727, is known to be teratogenic, and because belinostat may cause
teratogenicity and/or embryo-fetal lethality by virtue of targeting actively dividing
cells, women of child-bearing potential and men must agree to use adequate
contraception (hormonal or barrier method of birth control; abstinence) prior to study
entry and for the duration of study participation and for at least 6 months after the
last dose of study drugs. Should a woman become pregnant or suspect she is pregnant
while she or her partner is participating in this study, she should inform her
treating physician immediately. Men treated or enrolled on this protocol must also
agree to use adequate contraception prior to the study, for the duration of study
participation, and 3 months after completion of belinostat and SGI-110 (guadecitabine)
or ASTX727 administration
- Patients must be able to understand and willing to sign a written informed consent
document. Participants with impaired decision-making capacity (IDMC) who have a
legally-authorized representative (LAR) and/or family member available will also be
eligible
Exclusion Criteria:
- Patients with dedifferentiated, mesenchymal, or clear cell chondrosarcoma are not
eligible
- Patients who have not recovered from adverse events (AEs) (i.e., have residual
toxicities > grade 1) due to prior anti-cancer therapy are not allowed, with the
exceptions of alopecia and endocrinopathies from prior immunotherapy-based treatments
that are well-controlled with hormone replacement. In addition, the following time
periods must elapse between the last dose of prior anti-cancer treatment and
initiation of study treatment on this protocol:
- Cytotoxic chemotherapy or biologic, including immunotherapy: 28 days
- Small molecule targeted drug: 21 days or 5 half-lives, whichever is shorter. If 5
half-lives is shorter than 21 days, then 21 days applies.
- Radiation: 28 days, except for palliative radiation, for which 14 days applies
- Patients who are receiving any other investigational agents
- Patients with known history of allergic reactions or sensitivity attributed to
compounds of similar chemical or biologic composition to SGI-110 (guadecitabine), its
active metabolite decitabine, or ASTX727, or belinostat
- Chronic use of any medications or substances that are strong inhibitors of UGT1A1 is
not allowed. Patients must switch to alternative medications 7-14 days before
treatment with belinostat. Because the lists of these agents are constantly changing,
it is important to regularly consult a frequently-updated medical reference. As part
of the enrollment/informed consent procedures, the patient will be counseled on the
risk of interactions with other agents, and what to do if new medications need to be
prescribed or if the patient is considering a new over-the-counter medicine or herbal
product
- Patients with any known UGT1A1 polymorphism, heterozygous or homozygous, associated
with reduced function (UGT1A1*6, UGT1A1*28, or UGT1A1*60)
- Patients with uncontrolled intercurrent illness
- Patients with psychiatric illness/social situations that would limit compliance with
study requirements
- Pregnant women are excluded from this study because SGI-110 (guadecitabine) is a
derivative of decitabine, and ASTX727 contains the agent decitabine, which has the
potential for teratogenic or abortifacient effects, and because belinostat may cause
teratogenicity and/or embryo-fetal lethality by virtue of targeting actively dividing
cells. Because there is an unknown but potential risk for AEs in nursing infants
secondary to treatment of the mother with SGI-110 (guadecitabine), ASTX727 and
belinostat, breastfeeding should be discontinued
- Prolongation of the heart-rate corrected QT (QTc) interval >= 450 ms (i.e., grade 1 or
higher) on the screening electrocardiogram (ECG) prior to initiation of study
treatment. If baseline QTc on screening ECG is >= 450 ms (i.e., grade 1 or higher):
- Check potassium and magnesium serum levels, and
- Correct any identified hypokalemia and/or hypomagnesemia and repeat ECG to
confirm a QTc interval < 450 ms
